CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today announced a presentation at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held at the Moscone Convention Center in San Francisco, California. On October 24, 2007, Curis scientists presented a poster entitled “CUDC-101, a Synthetic and Potent HDAC, EGFR and Her2 Inhibitor, Effectively Inhibits Proliferation of Cancer Cell Lines” during a poster session. This presentation included discussions of a potential mechanism of action and the anticancer properties of CUDC-101, Curis’ proprietary small molecule drug candidate that Curis believes is the first single agent under development that simultaneously targets HDAC, EGFR and Her2, three validated cancer targets.
